Pancreatic Cancer Research

Clinical trialPhase 1Completed

A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer

A First-in-human Clinical Evaluation of the Novel Intravenous Contrast Agent SN132D in Patients With Breast and Pancreatic Cancer

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
23 August 2019
Ended
30 November 2022
Enrollment
14 participants
Sites
2
Primary outcomes
Number of treatment related adverse events (AEs)
Sponsor type
Industry
Results posted
No
Last update
9 December 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This phase I, first-in-human (FIH) study is open-label, non-randomised and non-placebo-controlled. The study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of a single intravenous dose of SN132D in approximately 24 patients with breast and pancreatic cancer. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.